changes in protein profiles in bortezomib applied multiple myeloma ...

More documents

Recommendations

Info

Wirk, B. 2011. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant 46(6): 771-83. Wolf, D. H. and Hilt, W. 2004. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochimica et Biophysica Acta 1695: 19-31. Wolters, D. A., Washburn, M. P. and Yates, J. R., 3rd. 2001. An automated multidimensional protein identification technology for shotgun proteomics. Analytical Chemistry 73: 5683-90. Yates, J. R. 1998. Mass spectrometry and the age of the proteome. Journal of Mass Spectrometry 33: 1-19. Zaidi, A. A. and Vesole, D. H. 2001. Multiple Myeloma: An Old Disease with New Hope for the Future. CA: a Cancer Journal for Clinicians 51(5): 273-285. Zwickl, P., Voges, D. and Baumeister, W. 1999. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philosophical Transactions of The Royal Society of London. Series B, Biological Sciences 354: 1501-1511. 101
A.1. RPMI-1640 Growth Medium APPENDIX A MEDIAS RPMI-1640, penicillin-streptomycin and fetal bovine serum (FBS) were obtained from Invitrogen (Paisley, UK). were added to 60 ml FBS (~10% of all volume) and 10 ml Penicillin-Streptomycin (~1%) 500 ml RPMI-1640 and mixed. 102
Page 1 and 2:
CHANGES IN PROTEIN PROFILES IN BORT
Page 3 and 4:
ACKNOWLEDGEMENTS First of all, with
Page 5 and 6:
ÖZET BORTEZOMĠB UYGULANAN MULTĠP
Page 7 and 8:
2.1.4.1.2. Two-Dimensional Gel Elec
Page 9 and 10:
LIST OF FIGURES Figure Page Figure
Page 11 and 12:
LIST OF TABLES Table Page Table 1.1
Page 13 and 14:
When normal cells in the body begin
Page 15 and 16:
Figure 1.2. Development of Cancer S
Page 17 and 18:
the myeloma cells does not help fig
Page 19 and 20:
A rare form of MM called Nonsecreto
Page 21 and 22:
1.2.3. Risk Factors for MM A risk f
Page 23 and 24:
of the mineralizations by adjusting
Page 25 and 26:
To measure the levels of red cells,
Page 27 and 28:
The levels of blood urea nitrogen (
Page 29 and 30:
By using the system introduced by D
Page 31 and 32:
1.2.7.2. Biology of The Proteasome
Page 33 and 34:
Figure 1.10. Ubiquitin-Proteasome P
Page 35 and 36:
Figure 1.12. Effect of Bortezomib o
Page 37 and 38:
encompasses the investigation of pr
Page 39 and 40:
of modification. Ubiquitin is a sma
Page 41 and 42:
the given cells. On the other hand,
Page 43 and 44:
is-acrylamide (N,N'-methylene-bisac
Page 45 and 46:
2.1.4.2. Detection of Protein Spots
Page 47 and 48:
ange of 600-2500 Da. This is the id
Page 49 and 50:
ions resolved by the mass analyzer
Page 51 and 52:
2.1.4.5.2. Mass Analyzers Figure 2.
Page 53 and 54:
There is no doubt that different ma
Page 55 and 56:
mask low-quantity proteins that may
Page 57 and 58:
3.1. Materials 3.1.1. Medias CHAPTE
Page 59 and 60:
3.2.5. Cell Proliferation Assay Ant
Page 61 and 62: After 72 hour incubation period at
Page 63 and 64: eceptors of the Tumor Necrosis Fact
Page 65 and 66: The preparation of stock BSA Standa
Page 67 and 68: 3.2.6.3. Detection of the Loss of M
Page 69 and 70: centrifugation, the supernatant was
Page 71 and 72: selected symmetrically to load the
Page 73 and 74: approximately 35 ml, the volume of
Page 75 and 76: After electrophoresis was finished,
Page 77 and 78: 7 Day Two: Reduction, Alkylation, a
Page 79 and 80: CHAPTER 4 RESULTS AND DISCUSSION 4.
Page 81 and 82: % Changes in Cytoplasmic/Mitochondr
Page 83 and 84: Table 4.1. Magnified Segments of Di
Page 85 and 86: Table 4.1. Magnified Segments of Di
Page 87 and 88: After labeling, black and red color
Page 89 and 90: 78 7 8 Y2S Y3S Table 4.2. Results o
Page 91 and 92: 80 12 S4Ca Table 4.2. Results of Di
Page 93 and 94: 82 27 Y5S Table 4.2. Results of Dif
Page 95 and 96: Spot 4, Ubiquitin-conjugating enzym
Page 97 and 98: is a transcriptional repressor, but
Page 99 and 100: activity and loss of mitochondrial
Page 101 and 102: distributed, but correlate with nat
Page 103 and 104: DeMartino, G. N. and Slaughter, C.
Page 105 and 106: proteomic analyses of a systematica
Page 107 and 108: Mahindraa, A., Hideshimab, T. and A
Page 109 and 110: Richardson, P. G., Hideshima, T. an
Page 111: Terpos, E. 2008. Bortezomib Directl
Page 115 and 116: Table B.1. Chemicals and Reagents U
Page 117 and 118: B.4.3. Standard Curve for BSA Table
Page 119 and 120: Urea (8M) 4.8 g CHAPS (%2) 0.2 g DT
Page 121 and 122: E. F. G. STOCK REAGENT PREPARATION
show all

changes in protein profiles in bortezomib applied multiple myeloma ...

Create successful ePaper yourself

Delete template?

Save as template?